To explore our 2015 Life Sciences Trends Report, download the PDF here or view an abbreviated overview below.

In 2015, life science companies will continue to find new avenues for decreasing costs, streamlining operations and improving shareholder value. Companies will maintain focus on therapies, technologies and investments that capitalize on their core business strengths, whether through partnerships or by divesting underperforming units. Commercialization and regulatory hurdles will remain a primary concern, particularly as generic & biologic drugs further penetrate world markets and governments and payers push for lower prices. A top priority for many life science companies is how to mitigate these challenges while also proving the value of their therapies to payers and patients.

2015 Life Sciences Trends

1. Strategy: Whether by divesting underperforming units or investing in complementary treatments, life science companies are looking for ways to improve their bottom line. As they examine their long-term strategies, they must take into account how expanding global patient populations and increasing competition from generic and biologic drugs will impact their business models.
2. Innovation and R&D: The melding of healthcare, technology and big data has, and will continue to, improve drug access, adherence and tracking over the coming years. With these advances – whether 3D printing, cloud-based platforms, or wearables – HIPAA and data storage, transmission and security are primary concerns. In addition, with the cost and skills that technology development requires, pharma and biotech companies will seek partnerships with tech and medical device companies, and vice versa.
3. Supply Chain: With expanding global patient populations, manufacturer consolidation, and big data and technology advancements, supply chain effectiveness is vital to business success. Life science companies are finding ways to better forecast demand and build more agile supply chains, capitalizing on real-time data solutions. In addition, to comply with U.S. Drug Supply Chain Security Act requirements, companies at the forefront are collaborating with trading partners and strategically investing in serialization solutions and pilot programs that can improve efficiency and drug safety
4. Commercialization: Globally, healthcare costs are impacting how life science companies bring therapies to market. Companies are focusing on building their pipelines in specialized areas, subsequently considering demand and the likelihood of regulatory approval. However, to garner an affable return, companies will need to collaborate with payers and providers to demonstrate improved adherence, innovation, and overall improved patient outcomes.

Reach out to our life sciences experts to see how our experts can partner with your business.